Objective: To validate the use of placenta accreta risk-antepartum (PAR-A) score as a predictive tool of clinical outcomes of placenta accreta spectrum (PAS).Methods: This is a prospective study, conducted in six PAS specialized centers in six different countries. The study was conducted between October 1, 2020 and March 31, 2021. Women who were provisionally diagnosed with PAS during pregnancy were considered eligible. A machine-learning-based PAR-A score was calculated. Diagnostic performance of the PAR-A score was evaluated using a receiver operating characteristic curve, for perioperative massive blood loss and admission to intensive care unit (ClinicalTrials.gov identifier NCT04525001).Results: Of 97 eligible women, 86 were included. PAS-associated massive blood loss occurred in 10 patients (11.63%). Median PAR-A scores of massive blood loss in the current cohort were 8.9 (interquartile range 6.9-14.1). In predicting massive blood loss, the area under the curve of PAR-A scores was 0.85 (95% confidence interval [CI] 0.74-0.95), which was not significantly different from the original cohort (P = 0.2). PAR-A score prediction of intensive care unit admission was slightly higher compared with the original cohort (0.88, 95% CI 0.81-0.95; P = 0.06). Conclusion:PAR-A score is a novel scoring system of PAS outcomes, which showed external validity based on current data.
Background: The Presence of palpable breast mass may be an indication of breast cancer. Early and accurate diagnosis for the breast masses is important for therapeutic purpose. Purpose: To assess the diagnostic accuracy of mammographic and sonographic findings in the differentiation of palpable breast masses taking histopathology as a gold standard. Materials and Methods: 134 females were involved in the study. Sonographic and mammographic findings of palpable breast masses were obtained with the help of which diagnostic accuracy of ultrasound and mammography was calculated while taking histopathology as a gold standard. Results: Mean age in 134 females was found to be 44.2±4.7 years. Sn, Sp, PPV, NPV, disease prevalence and accuracy of ultrasound in diagnosis of palpable breast lumps were 99.09%, 79.17%, 95.61%, 95.00%, 82.09% and 95.52% respectively. Sn, Sp, PPV, NPV and accuracy of mammography in diagnosis of palpable breast lumps were 95.45%, 62.50%, 92.11%, 75.00% and 89.55% while disease prevalence was same as that of ultrasound i.e. 82.09% respectively. Conclusion: Ultrasound showed higher diagnostic accuracy in the evaluation of palpable breast masses than mammography while taking histopathology as a gold standard. It is noteworthy in differentiating breast masses.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.